Endothelial cell (EC) is the first point of contact between the allograft and the recipient's immune system. In this process, a source of non-HLA antigens stimulates a humoral immune response. Using primary human aortic EC (HAEC) and the XM one assay, EC crossmatch (ECXM) could be used to identify patient sera containing antibodies against EC. Creative Biolabs provides ECXM assay to detect non-human leukocyte antigen (HLA) antibodies, which have been implicated in antibody-mediated rejections.
Firstly, blood is collected from the donor and peripheral blood mononuclear cells (PBMCs) are isolated. Endothelial precursor cells are then isolated and probed by recipient antibodies. The recipient antibodies are then tagged with fluorescently labeled antihuman IgG or IgM antibodies. Finally, the antibody-bound precursor cells run through a flow cytometer to determine the reactivity toward donor endothelial antigens.
Fig.1 Diagram of ECXM assay. (Gates, 2017)
EC constitutes the first point of contact between the transplanted organ and the recipient's immune system. Antibodies reactive with donor endothelial cell antigens have been implicated in cases of humoral rejection in the absence of HLA antibodies. ECXM identifies antibodies to non-HLA antigens expressed on endothelial cells. The results are reported as the median channel shift (MCS) over the negative control sera. A positive result is >50 MCS.
Creative Biolabs provides a comprehensive ECXM service and in vitro diagnostic kit which is used for the isolation of endothelial precursor cells and preparation of samples for analysis of IgM and IgG antibodies specific for these cells.
As a leader in HLA antibody detection, Creative Biolabs offers a full range of HLA Antibody and Non-HLA Antibody detection assay for the transplant diagnostics segment. We also offer a wide range of singleplex kits. For more information, please feel free to contact us directly.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION